With governments such as China channeling fresh fiscal spending into healthcare and social security, artificial intelligence in medicine is moving from theory into real projects that need practical solutions. That creates a window for investors who want exposure to AI tools that may help clinicians, hospitals, and researchers work smarter. This article highlights three Transformative AI Healthcare stocks from our screener that show how this theme is taking shape.
The three stocks below are a sample of the AI healthcare theme, and the full screen on Simply Wall St surfaced 6 more companies with equally compelling narratives that are not covered here. To go deeper into the theme, analyze and identify your own highest conviction ideas straight from the Transformative Artificial intelligence (AI) Healthcare Stocks screener .
Chugai Pharmaceutical (TSE:4519)
Overview:Chugai Pharmaceutical is a Japan based drug company focused on oncology and other specialty biologic therapies. It is now working with Phylo to apply an agentic AI platform across its drug discovery workflow to speed up target identification and biomedical research.
Operations:Chugai generates about ¥1.34t in revenue from pharmaceuticals, with ¥486,188 million reported in Japan and the remainder largely captured in segment adjustments tied to its broader operations.
Market Cap:¥11.60t
Chugai Pharmaceutical offers exposure to a large biologics and oncology portfolio while also connecting to AI driven drug discovery through its Phylo partnership. This partnership applies agentic AI to single cell data, human genetics and disease biology to refine targets earlier in the R&D cycle. The company reports high profitability, with net margins around the mid 30s and return on equity above 23%, which can help fund these AI initiatives without stretching the balance sheet. The catch is heavy dependence on a few blockbuster drugs and close ties to Roche, so future results may depend on how quickly the AI enabled pipeline contributes to more diversified revenue rather than remaining focused on early stage research activity.
Chugai Pharmaceutical is using high margins and strong returns to bankroll AI driven drug discovery, yet the real story sits in how resilient those profits might be if its blockbusters stumble. Review the 3 key rewards and 1 important warning sign
Wellness Communications (TSE:366A)
Overview:Wellness Communications runs Growbase, a cloud based health management platform that centralizes employee health data for companies, and SUZAKU, an AI driven talent and HR system that uses organizational psychology to support predictive insights into workforce health and performance, alongside other wellness and occupational health services in Japan.
Market Cap:¥14.27 billion
Investors looking at AI in healthcare may monitor how Wellness Communications monetizes Growbase and SUZAKU, since these AI driven platforms sit at the intersection of health data, diagnostics support, and workforce management. Reported earnings growth of 5.9% and revenue growth of 11.1% sit alongside a P/E of 17.4x, compared with peers at 22.1x. Margins are reported at 5.6% and described as improving, supported by subscription like revenue. Potential concerns include limited board independence at 40% and reliance on borrowing rather than customer deposits, which may raise governance and funding questions as data privacy and infrastructure costs change. The upcoming Q1 2027 results on 14 August 2026 may provide more detail on the adoption and commercial progress of these AI products.
Wellness Communications combines 11.1% reported revenue growth with AI driven health platforms that many investors may still be underestimating. Scan the analyst forecasts for Wellness Communications to see what the current trajectory could be masking.
eWeLLLtd (TSE:5038)
Overview:eWeLLLtd runs iBow, a cloud based electronic medical record and workflow system for home visit nursing in Japan, with AI assisted home nursing reports that automate documentation and analytics, and surrounds this with billing, attendance, factoring, and e learning tools for home based care providers.
Operations:eWeLLLtd generates about ¥3,781 million in revenue from providing services to home visit nursing stations.
Market Cap:¥32.58 billion
eWeLLLtd puts AI directly into day to day home nursing through its iBow platform, where AI written reports and analytics aim to cut paperwork and reduce errors for overstretched visiting nurses. Earnings growth of 21.5% over the past year and net margins around 31.9% describe a model that converts that efficiency story into profit, backed by an experienced board with an average tenure of roughly nine years. At the same time, a premium P/E and recent share price volatility mean expectations for AI driven growth are already high. Any slowdown in iBow adoption or margin pressure could affect sentiment quickly. For investors who want targeted exposure to AI in remote, real world care settings, it is a business worth watching closely.
eWeLLLtd's 21.5% earnings growth and 31.9% net margins suggest the story could be bigger than iBow alone. Review the analyst forecasts for eWeLLLtd to see what expectations might be missing about its next chapter
Seeking Fresh Alternatives Beyond Healthcare?
Some of the most interesting breakouts start quietly. Use these fresh stock lists before momentum flies, while the data still matters and remains under the radar for now.
-
Spot companies quietly building strength in core fundamentals by scanning the curated list of solid balance sheet and fundamentals (41 results) before the crowd catches the next wave of quality.
-
Explore potential exposure to income streams by checking the hand picked 31 dividend fortresses while yields still compensate you for the risk.
-
Review the focused 38 power grid technology and infrastructure stocks ahead of any potential infrastructure-related shifts in utilities and suppliers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
